BriaCell Therapeutics Competitors

Bellicum Pharmaceuticals (NASDAQ:BLCM) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

Bellicum Pharmaceuticals has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bellicum Pharmaceuticals and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

BriaCell Therapeutics has lower revenue, but higher earnings than Bellicum Pharmaceuticals.

Institutional and Insider Ownership

20.2% of Bellicum Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. 3.8% of Bellicum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Bellicum Pharmaceuticals and BriaCell Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bellicum Pharmaceuticals and BriaCell Therapeutics, as provided by MarketBeat.

Bellicum Pharmaceuticals currently has a consensus target price of $4.50, indicating a potential upside of 28.21%.

Summary

Bellicum Pharmaceuticals beats BriaCell Therapeutics on 5 of the 7 factors compared between the two stocks.

NTN Buzztime (NYSEAMERICAN:NTN) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

NTN Buzztime has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares NTN Buzztime and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

NTN Buzztime has higher revenue and earnings than BriaCell Therapeutics.

Institutional and Insider Ownership

6.3% of NTN Buzztime shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. 24.2% of NTN Buzztime shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares NTN Buzztime and BriaCell Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NTN Buzztime and BriaCell Therapeutics, as provided by MarketBeat.

Summary

NTN Buzztime beats BriaCell Therapeutics on 5 of the 9 factors compared between the two stocks.

Sonoma Pharmaceuticals (NASDAQ:SNOA) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

Sonoma Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sonoma Pharmaceuticals and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

Sonoma Pharmaceuticals has higher revenue and earnings than BriaCell Therapeutics.

Institutional and Insider Ownership

9.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. 5.6% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Sonoma Pharmaceuticals and BriaCell Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sonoma Pharmaceuticals and BriaCell Therapeutics, as provided by MarketBeat.

Summary

Sonoma Pharmaceuticals beats BriaCell Therapeutics on 5 of the 9 factors compared between the two stocks.

XTL Biopharmaceuticals (NASDAQ:XTLB) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Profitability

This table compares XTL Biopharmaceuticals and BriaCell Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

8.6% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

XTL Biopharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for XTL Biopharmaceuticals and BriaCell Therapeutics, as provided by MarketBeat.

Valuation & Earnings

This table compares XTL Biopharmaceuticals and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

BriaCell Therapeutics (OTCMKTS:BCTXF) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares BriaCell Therapeutics and Eledon Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 2.2% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BriaCell Therapeutics and Eledon Pharmaceuticals, as provided by MarketBeat.com.

Eledon Pharmaceuticals has a consensus target price of $29.50, indicating a potential upside of 158.09%.

Valuation and Earnings

This table compares BriaCell Therapeutics and Eledon Pharmaceuticals' gross revenue, earnings per share and valuation.

BriaCell Therapeutics (OTCMKTS:BCTXF) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares BriaCell Therapeutics and Novus Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 2.2% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BriaCell Therapeutics and Novus Therapeutics, as provided by MarketBeat.com.

Novus Therapeutics has a consensus target price of $50.75, indicating a potential upside of 344.01%.

Valuation and Earnings

This table compares BriaCell Therapeutics and Novus Therapeutics' gross revenue, earnings per share and valuation.